EA200601414A1 - Способ контроля потребления пищи - Google Patents

Способ контроля потребления пищи

Info

Publication number
EA200601414A1
EA200601414A1 EA200601414A EA200601414A EA200601414A1 EA 200601414 A1 EA200601414 A1 EA 200601414A1 EA 200601414 A EA200601414 A EA 200601414A EA 200601414 A EA200601414 A EA 200601414A EA 200601414 A1 EA200601414 A1 EA 200601414A1
Authority
EA
Eurasian Patent Office
Prior art keywords
food intake
methods
control
eating
food consumption
Prior art date
Application number
EA200601414A
Other languages
English (en)
Russian (ru)
Inventor
Нир Барак
Original Assignee
Мор Рисерч Эппликейшнз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL16159504A external-priority patent/IL161595A0/xx
Application filed by Мор Рисерч Эппликейшнз Лтд. filed Critical Мор Рисерч Эппликейшнз Лтд.
Publication of EA200601414A1 publication Critical patent/EA200601414A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA200601414A 2004-04-22 2005-04-21 Способ контроля потребления пищи EA200601414A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL16159504A IL161595A0 (en) 2004-04-22 2004-04-22 Betahistine as a weight management agent
US67029005P 2005-04-12 2005-04-12
PCT/IL2005/000440 WO2005101979A2 (en) 2004-04-22 2005-04-21 Method of food intake management

Publications (1)

Publication Number Publication Date
EA200601414A1 true EA200601414A1 (ru) 2007-02-27

Family

ID=35197421

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601414A EA200601414A1 (ru) 2004-04-22 2005-04-21 Способ контроля потребления пищи

Country Status (10)

Country Link
US (5) US20060084686A1 (enExample)
EP (1) EP1737454A4 (enExample)
JP (1) JP2007533733A (enExample)
KR (1) KR20060134041A (enExample)
BR (1) BRPI0506807A (enExample)
CA (1) CA2553309A1 (enExample)
EA (1) EA200601414A1 (enExample)
IL (1) IL176793A0 (enExample)
NO (1) NO20063221L (enExample)
WO (1) WO2005101979A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005101979A2 (en) 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
US20080051440A1 (en) * 2004-04-22 2008-02-28 Mor Research Applications Ltd. Compositions for weight management
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
US8242148B2 (en) * 2005-12-23 2012-08-14 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
US8748419B2 (en) * 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
UA98938C2 (ru) * 2006-06-16 2012-07-10 Теракос, Инк. Лечение психологических состояний с применением антагонистов мускариновых рецепторов м1
US20080033019A1 (en) * 2006-08-07 2008-02-07 Duke University Cholesterol lowering drug combination
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
ES2830073T3 (es) * 2007-04-11 2021-06-02 Omeros Corp Composiciones y métodos para la profilaxis y el tratamiento de adicciones
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
US8586634B2 (en) * 2007-06-15 2013-11-19 University Of Florida Research Foundation, Inc. Therapeutic compounds
US8642631B2 (en) 2008-05-27 2014-02-04 University Of Melbourne Methods of treating mammals with eustachian tube dysfunctions
WO2011009012A1 (en) * 2009-07-15 2011-01-20 Columbia University METHODS OF SUPPRESSING APPETITE BY THE ADMINISTRATION OF ANTAGONISTS OF THE SEROTONIN HTR1a or HTR2b RECEPTORS OR INHIBITORS OF TPH2
US20110021507A1 (en) * 2009-07-22 2011-01-27 Theracos, Inc. Inhibiting antipsychotic-induced weight gain
PH12012500628A1 (en) * 2009-10-13 2012-10-22 Nestec Sa Systems for evaluating dietary intake and methods of using same
SMT201900357T1 (it) 2009-12-04 2019-07-11 Alkermes Pharma Ireland Ltd Derivati di morfinano per trattamento di abuso di sostanze stupefacenti
US20110143704A1 (en) 2009-12-14 2011-06-16 William Lorentz Specialized dial a chip
SI2608670T1 (sl) 2010-08-23 2019-04-30 Alkermes Pharma Ireland Limited Postopki za zdravljenje pridobivanja teže, ki je posledica uporabe antipsihotičnih zdravil
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US20140072936A1 (en) * 2012-09-07 2014-03-13 Patrick D. Herron Method of Tracking Consumption and Associated Effects
NZ631018A (en) 2013-05-24 2017-12-22 Alkermes Pharma Ireland Ltd Morphan and morphinan analogues, and methods of use
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
RU2540911C2 (ru) * 2013-06-11 2015-02-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ коррекции синдрома ночной еды у пациентов с тревожно-депрессивными расстройствами
DE102015202695A1 (de) * 2015-02-13 2016-08-18 Carl Zeiss Smt Gmbh Prüfvorrichtung sowie Verfahren zum Prüfen eines Spiegels
AR111699A1 (es) * 2017-02-02 2019-08-14 Otolanum Ag Composición farmacéutica que comprende betahistina
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
KR20250154480A (ko) * 2023-02-28 2025-10-28 바이오하벤 테라퓨틱스 리미티드 강박 관련 장애, 틱 장애 및 글루타메이트 흥분독성 관련 장애의 치료 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1577871A (en) * 1976-05-28 1980-10-29 Unimed Inc Prevention of myocardial infarction
JPS55154915A (en) * 1979-05-21 1980-12-02 Jiyan Sadeia Shieruki Medicine mold
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
DE69911058T2 (de) 1998-12-23 2004-06-03 G.D. Searle Llc, Chicago Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
WO2000039098A1 (en) * 1998-12-23 2000-07-06 Maxim Pharmaceuticals, Inc. Synthesis of histamine dihydrochloride
IT1309591B1 (it) 1999-03-05 2002-01-24 Formenti Farmaceutici Spa Composizioni a rilascio controllato di betaistina.
WO2000071106A2 (en) * 1999-05-19 2000-11-30 Astrazeneca Ab Method of treating weight gain
PL202935B1 (pl) * 2000-03-08 2009-08-31 Awd Pharma Gmbh & Co Kg Doustny preparat farmaceutyczny o zmiennie nastawianej charakterystyce uwalniania oraz sposób wytwarzania takiego preparatu
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
CA2444429A1 (en) 2001-04-11 2002-11-07 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
US20030162824A1 (en) 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
US20040110803A1 (en) 2002-09-13 2004-06-10 Hossein Dovlatabadi Methods and compositions for the use of D-malic acid to decrease serum triglyceride, cholesterol and lipoprotein levels
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
WO2005101979A2 (en) * 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
US20080051440A1 (en) * 2004-04-22 2008-02-28 Mor Research Applications Ltd. Compositions for weight management
US20060039866A1 (en) 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders

Also Published As

Publication number Publication date
NO20063221L (no) 2006-10-06
JP2007533733A (ja) 2007-11-22
US7737165B2 (en) 2010-06-15
WO2005101979A3 (en) 2006-07-27
US20060073217A1 (en) 2006-04-06
US20080004322A1 (en) 2008-01-03
IL176793A0 (en) 2006-10-31
US20080051439A1 (en) 2008-02-28
CA2553309A1 (en) 2005-11-03
WO2005101979A2 (en) 2005-11-03
BRPI0506807A (pt) 2007-05-29
US20060084686A1 (en) 2006-04-20
EP1737454A4 (en) 2007-08-08
US20080004324A1 (en) 2008-01-03
EP1737454A2 (en) 2007-01-03
KR20060134041A (ko) 2006-12-27

Similar Documents

Publication Publication Date Title
EA200601414A1 (ru) Способ контроля потребления пищи
MY156243A (en) Treatment for diabetes in patients inappropriate for metformin therapy
MX358618B (es) Usos de inhibidores de dpp iv.
NO20065560L (no) Anvendelse av IL-17-uttrykking for a forutsi hudinflammasjon, fremgangsmater for behandling.
CY1113848T1 (el) Μικροοργανισμοι για τη βελτιωση της υγειας ατομων με διαταραχες που σχετιζονται με την προσληψη γλουτενης
TW200732347A (en) VEGF analogs and methods of use
NO20073882L (no) Human anti-interferon gamma antistoffer og fremgangsmater for anvendelser derav
BRPI0411784A (pt) anticorpos contra interleucina -22 e usos para os mesmos
MX2009006672A (es) Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
ECSP077222A (es) Anticuerpos monoclonales humanos contra interleucina-4 humana (il-4)
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
WO2008029169A3 (en) Method of treating respiratory disorders
NO20070996L (no) Fremgangsmate for behandling av CCR2 medierte sykdommer eller lidelser
DE602005027400D1 (de) Il-22 zur behandlung von fettleibigkeit, diabetes, hyperlipidämie, hyperglykämie und insulinresistenz
Bird We need to talk: the case for psychological therapy on the NHS
WO2005115446A3 (en) Detection and use of prolylcarboxypeptidase
TW200716225A (en) Combination therapy for treating obesity or maintaining weight loss
TW200833336A (en) Method of treatment of obesity
BRPI0610454B8 (pt) método para tratar ou prevenir diabetes tipo-2
RU2003130720A (ru) Способ коррекции нарушений адаптации у больных синдромом хронической усталости
WO2019243898A8 (en) Methods for improving response to anti-lif antibody treatment in individuals with cancer
RU2008115909A (ru) Способ зондового питания больных с черепно-мозговой травмой
EA200870108A1 (ru) Мутанты фсг
Balhara et al. IgE Modulates The Expression Of SmMLCK In Human Airway Smooth Muscle Cells
MX2025000385A (es) Metabolitos de belumosudil y usos de los mismos en el tratamiento de la enfermedad cronica del injerto contra el hospedero